Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Contribution margin per pair beyond breakeven point of 19,000 pairs = $7.50 ($40 $31 $1.50) per pair
Large-scale, randomized trials remain limited, largely due to funding priorities favoring patentable therapies over peptides like this
A Novel ER Stress Inducer ONC201 Exerts p53-independent Apoptosis in Hematological Malignancies and Leukemic Stem/Progenitor Cells by Targeting ER Stress Response, mTOR and MCL1
The formulation was designed for researchers studying multi-pathway approaches to tissue regeneration and skin repair, where the mechanisms of all three compounds may interact
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
US$ 25.33
US$ 27.81
US$ 21.60
